PreprintCC BY-NC-NDmedRxiv15 Sep 2026

Real-World Effectiveness of Maternal RSVpreF Vaccination and Durability of Infant Protection

H. Xu¹
C. Aparicio-Llorente
A. Wats
B. L. Araujo
J. M. Ganem
I. O. Oliva
E. D. Shapiro
N. N. Brodsky
P. L. Aronson
N. D. Grubaugh
C. L. Lucas
L. M. Niccolai

5 more authors

J. L. Warren
L. Kennedy-Shaffer
V. E. Pitzer
D. M. Weinberger
C. R. Oliveira

¹Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

Abstract

In this test-negative study, the effectiveness of the maternal RSVpreF vaccine among infants <6 months was 73.9% against medically attended respiratory syncytial virus (RSV) infection and 86.3% against RSV-associated hospitalization. Maternal RSVpreF and nirsevimab had comparable initial effectiveness, but effectiveness of RSVpreF waned approximately 1.7 times more rapidly.

Cost-utility of respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for disease prevention among colombian infants.
Jaime Ordóñez, Beatriz Ospina
BMC health services research3 Aug 2026Peer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMC
Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: a retrospective test-negative case control study
Sara Yee Tartof, Negar Aliabadi, Evan J Zasowski +18
The Lancet Regional Health - Americas27 May 2026Peer-reviewedCC BY-NC-ND13 citedEpidemiology & public healthOpenAlex
Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients
Victoria G. Hall, Adrian A. Alexander, Madeline R. Kern-Smith +15
JAMA Network Open6 Nov 2026Peer-reviewedCC BY 4.0General medicineCrossref
Histomonas meleagridis infection and vaccination protection in chickens -- a metabolomics study
V. A. Nguyen, T. Meuronen, A. Lihtamo +6
bioRxiv24 Sep 2026PreprintAll rights reservedFull textPharmacology & toxicologybioRxiv
Durability of respiratory syncytial virus vaccine effectiveness for the elderly against infection and severe outcomes: A retrospective observational study with 3-year follow-up using electronic health records
Taito Kitano, Shinya Tsuzuki, Haruhisa Fukuda +1
Vaccine: X7 Nov 2026Peer-reviewedCC BYFull textEpidemiology & public healthDOAJ

Cite

BibTeX RIS

BibTeX

@misc{xu2026realworld,
  title = {{Real-World Effectiveness of Maternal RSVpreF Vaccination and Durability of Infant Protection}},
  author = {H. Xu and C. Aparicio-Llorente and A. Wats and B. L. Araujo and J. M. Ganem and I. O. Oliva and E. D. Shapiro and N. N. Brodsky and P. L. Aronson and N. D. Grubaugh and C. L. Lucas and L. M. Niccolai and J. L. Warren and L. Kennedy-Shaffer and V. E. Pitzer and D. M. Weinberger and C. R. Oliveira},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.15.26363141},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.15.26363141v1},
  note = {CC BY-NC-ND},
}

RIS

TY  - UNPB
TI  - Real-World Effectiveness of Maternal RSVpreF Vaccination and Durability of Infant Protection
AU  - H. Xu
AU  - C. Aparicio-Llorente
AU  - A. Wats
AU  - B. L. Araujo
AU  - J. M. Ganem
AU  - I. O. Oliva
AU  - E. D. Shapiro
AU  - N. N. Brodsky
AU  - P. L. Aronson
AU  - N. D. Grubaugh
AU  - C. L. Lucas
AU  - L. M. Niccolai
AU  - J. L. Warren
AU  - L. Kennedy-Shaffer
AU  - V. E. Pitzer
AU  - D. M. Weinberger
AU  - C. R. Oliveira
PY  - 2026
DA  - 2026/09/15
PB  - medRxiv
DO  - 10.64898/2026.09.15.26363141
UR  - https://www.medrxiv.org/content/10.64898/2026.09.15.26363141v1
AB  - In this test-negative study, the effectiveness of the maternal RSVpreF vaccine among infants <6 months was 73.9% against medically attended respiratory syncytial virus (RSV) infection and 86.3% against RSV-associated hospitalization. Maternal RSVpreF and nirsevimab had comparable initial effectiveness, but effectiveness of RSVpreF waned approximately 1.7 times more rapidly.
ER  -

Abstract

Related

Cite